Department of Internal Medicine 1, Faculty of Medicine, Shimane University, 89-1 Enya-cho, Izumo, Shimane, 693-8501, Japan.
Osteoporos Int. 2011 Jan;22(1):187-94. doi: 10.1007/s00198-010-1184-7. Epub 2010 Feb 18.
Although recent animal studies have shown that undercarboxylated osteocalcin acts as a hormone regulating glucose metabolism and fat mass, little is known about the relationships in humans. We reported here for the first time that undercarboxylated osteocalcin were associated with glucose/fat metabolism in patients with type 2 diabetes.
Recent studies have shown that undercarboxylated osteocalcin (ucOC) acts as a hormone regulating glucose metabolism and fat mass. We investigated the relationship between ucOC as well as other bone turnover markers [serum OC, bone-specific alkaline phosphatase (BAP), and urinary N-terminal cross-linked telopeptide of type-I collagen] versus serum levels of glucose, fasting serum C-peptide, and adiponectin as well as the amount of fat mass in type 2 diabetes.
A total of 180 men and 109 postmenopausal women were consecutively recruited, and radiographic and biochemical characteristics were collected. Fat mass was measured by dual X-ray absorptiometry (DXA) and computed tomography (CT).
In men, ucOC negatively correlated with percent trunk fat (%trunk fat; by DXA) and visceral/subcutaneous fat ratio (by CT) as well as fasting plasma glucose and HbA(1c) (at least p < 0.05). Multiple regression analysis showed that these associations were still significant independent of age, duration of diabetes, body stature, and renal function as well as glucose or fat metabolism, whereas BAP, another bone formation marker, did not correlate with any variable. On the other hand, although ucOC also negatively correlated with %fat and %trunk fat as well as HbA(1c) (at least p < 0.05) in postmenopausal women, we found no significant association in multiple regression analysis.
These findings suggest that ucOC is associated with plasma glucose level and fat mass in men with type 2 diabetes.
尽管最近的动物研究表明,非羧化骨钙素作为一种调节葡萄糖代谢和脂肪量的激素发挥作用,但人们对其在人类中的关系知之甚少。我们首次报道,2 型糖尿病患者的非羧化骨钙素与葡萄糖/脂肪代谢有关。
最近的研究表明,非羧化骨钙素(ucOC)作为一种调节葡萄糖代谢和脂肪量的激素发挥作用。我们研究了 ucOC 与其他骨转换标志物(血清 OC、骨碱性磷酸酶(BAP)和尿型 I 胶原 N 端交联肽)与 2 型糖尿病患者的血清葡萄糖、空腹血清 C 肽和脂联素水平以及脂肪量之间的关系。
共连续招募 180 名男性和 109 名绝经后女性,收集放射学和生物化学特征。脂肪量通过双能 X 线吸收法(DXA)和计算机断层扫描(CT)进行测量。
在男性中,ucOC 与躯干脂肪百分比(通过 DXA)和内脏/皮下脂肪比例(通过 CT)以及空腹血糖和糖化血红蛋白(HbA1c)呈负相关(至少 p < 0.05)。多元回归分析表明,这些关联在排除年龄、糖尿病病程、身高和肾功能以及葡萄糖或脂肪代谢等因素后仍然显著,而另一种骨形成标志物 BAP 与任何变量均无相关性。另一方面,尽管 ucOC 也与绝经后女性的%脂肪和%躯干脂肪以及 HbA1c 呈负相关(至少 p < 0.05),但在多元回归分析中未发现显著相关性。
这些发现表明,ucOC 与 2 型糖尿病男性的血浆葡萄糖水平和脂肪量有关。